EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adverse Drug Events Associated With Selective Serotonin Reuptake Inhibitor Use During Pregnancy: A Pharmacovigilance Analysis Based on Real‐World Data

Lu Wang, Rui Xiong, Hengxu Liu, Shipeng Zhang, Yongtao Tong, Guangtao Hu, Xiaodan Lai

Journal of Clinical Pharmacy and Therapeutics · 2026-01 · 2026 (1)

DOI: 10.1155/jcpt/2842468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 24.03.2026. Verfasst von Lu Wang und 6 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The study aims at providing valuable insights of safety of SSRI during pregnancy that assist the surveillance and possibly a timely intervention, by exploring the serious adverse drug events (ADEs) of SSRIs during pregnancy by conducting a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS), and investigating comprehensive influencing factors of ADEs in real‐word settings.

Methods

The association between 5 commonly used SSRIs (i.e., paroxetine, fluoxetine, escitalopram, sertraline and citalopram) and ADEs was assessed by performing a disproportionality analysis. Cases were classified into serious and nonserious ADE groups based on their clinical outcomes, and their general characteristics were described. Influencing factors of occurrence of serious ADEs were identified through logistic regression.

Conclusions

We first investigated ADEs associated with SSRI use during pregnancy based on real‐world data. Our research highlights the clinical significance of proper SSRI option, depression severity and concomitant drug use in reducing serious ADEs.

Zitieren

APA

Wang, L., Xiong, R., Liu, H., Zhang, S., Tong, Y., Hu, G., & Lai, X. (2026). Adverse Drug Events Associated With Selective Serotonin Reuptake Inhibitor Use During Pregnancy: A Pharmacovigilance Analysis Based on Real‐World Data. Journal of Clinical Pharmacy and Therapeutics, 2026(1). https://doi.org/10.1155/jcpt/2842468

Vancouver

Wang L, Xiong R, Liu H, Zhang S, Tong Y, Hu G, et al. Adverse Drug Events Associated With Selective Serotonin Reuptake Inhibitor Use During Pregnancy: A Pharmacovigilance Analysis Based on Real‐World Data. Journal of Clinical Pharmacy and Therapeutics. 2026;2026(1). doi:10.1155/jcpt/2842468

BibTeX
@article{Wang2026,
  author = {Wang, Lu and Xiong, Rui and Liu, Hengxu and Zhang, Shipeng and Tong, Yongtao and Hu, Guangtao and Lai, Xiaodan},
  title = {Adverse Drug Events Associated With Selective Serotonin Reuptake Inhibitor Use During Pregnancy: A Pharmacovigilance Analysis Based on Real‐World Data},
  journal = {Journal of Clinical Pharmacy and Therapeutics},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jcpt/2842468}
}
Kostenlos starten →